阿尔茨海默病基因检测与长期护理保险。
Genetic testing for Alzheimer's and long-term care insurance.
机构信息
Duke University, Durham, North Carolina, USA.
出版信息
Health Aff (Millwood). 2010 Jan-Feb;29(1):102-8. doi: 10.1377/hlthaff.2009.0525.
Abstract
A genetic marker known as apolipoprotein E provides a clear signal of a person's risk of developing Alzheimer's disease and thus that person's future need for long-term care. People who find that they have the variant of the trait that increases Alzheimer's disease risk are more likely to purchase long-term care insurance after receiving this information. If the information is widely introduced into the insurance market, coverage rates could be affected in different ways, depending on who possesses that information. Policymakers will eventually need to confront the issue of the use of this and other markers in the pricing of long-term care insurance.
摘要
一种被称为载脂蛋白 E 的遗传标记物为个体罹患阿尔茨海默病的风险提供了明确信号，也预示着该个体对长期护理的未来需求。那些发现自己具有增加阿尔茨海默病风险的特征变体的人，在收到这一信息后更有可能购买长期护理保险。如果该信息被广泛引入保险市场，那么根据谁拥有这些信息，保险覆盖范围可能会受到不同的影响。政策制定者最终将需要面对在长期护理保险定价中使用这种及其他标记物的问题。
相似文献
1
Genetic testing for Alzheimer's and long-term care insurance.
Health Aff (Millwood). 2010 Jan-Feb;29(1):102-8. doi: 10.1377/hlthaff.2009.0525.
2
Long-term care: home- and community-based services. Issue brief.
Issue Brief Health Policy Track Serv. 2011 Jan 3:1-23.
3
Public versus private sector insurance for long-term care: issues and prospects.
J Health Hum Serv Adm. 1994 Fall;17(2):162-78.
4
Medicaid. Will the public program neglect the poor to pay for the elderly?
Hosp Health Netw. 1995 May 20;69(10):28-30, 32, 34.
5
Financing long-term care: a practical mix of public and private.
J Health Polit Policy Law. 1992 Fall;17(3):403-23; discussion 435-8. doi: 10.1215/03616878-17-3-403.
6
Multiple Dimensions of Private Information: Evidence from the Long-Term Care Insurance Market.
Am Econ Rev. 2006 Sep 1;96(4):938-958. doi: 10.1257/aer.96.4.938.
7
Long-term care and the private insurance market.
EBRI Issue Brief. 1995 Jul(163):1-23.
8
State reforms in long term care: budgets, waivers, and state initiatives as catalysts.
J Long Term Home Health Care. 1994 Winter;13(1):17-28.
9
Repeal of the Boren amendment: potential implications for long-term care.
Policy Brief Commonw Fund. 1998 Jun(283):1-6.
10
Aging: the endgame.
Newsweek. 1996 Sep 30;128(14):53.
引用本文的文献
1
What Can Economics Say about Alzheimer's Disease?
J Econ Lit. 2023 Jun;61(2):428-470. doi: 10.1257/jel.20211660.
2
Potential corporate uses of polygenic indexes: Starting a conversation about the associated ethics and policy issues.
Am J Hum Genet. 2024 May 2;111(5):833-840. doi: 10.1016/j.ajhg.2024.03.010.
3
Perspectives of People At-Risk on Parkinson's Prevention Research.
J Parkinsons Dis. 2024;14(3):399-414. doi: 10.3233/JPD-230436.
4
Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
J Am Geriatr Soc. 2021 Nov;69(11):3203-3211. doi: 10.1111/jgs.17362. Epub 2021 Jul 12.
5
Precision Medicine and Big Data: The Application of an Ethics Framework for Big Data in Health and Research.
Asian Bioeth Rev. 2019 Sep 30;11(3):275-288. doi: 10.1007/s41649-019-00094-2. eCollection 2019 Sep.
6
Genetic testing for neurodegenerative diseases: Ethical and health communication challenges.
Neurobiol Dis. 2020 Jul;141:104871. doi: 10.1016/j.nbd.2020.104871. Epub 2020 Apr 14.
7
Genetic Sample Provision Among National Alzheimer's Coordinating Center Participants.
J Alzheimers Dis. 2019;69(1):123-133. doi: 10.3233/JAD-181159.
8
From Fraternities to DNA: The Challenge Genetic Prediction Poses to Insurance Markets.
Milbank Q. 2019 Mar;97(1):40-43. doi: 10.1111/1468-0009.12365. Epub 2019 Jan 4.
9
Clinical implications of APOE genotyping for late-onset Alzheimer's disease (LOAD) risk estimation: a review of the literature.
J Neural Transm (Vienna). 2019 Jan;126(1):65-85. doi: 10.1007/s00702-018-1934-9. Epub 2018 Oct 31.
10
Tensions in ethics and policy created by National Precision Medicine Programs.
Hum Genomics. 2018 Apr 17;12(1):22. doi: 10.1186/s40246-018-0151-9.
本文引用的文献
1
Dynamic Inefficiencies in Insurance Markets: Evidence from Long-Term Care Insurance.
Am Econ Rev. 2005 May;95(2):224-28. doi: 10.1257/000282805774669808.
2
The Private Market for Long-Term Care Insurance in the U.S.: A Review of the Evidence.
J Risk Insur. 2009 Feb 10;76(1):5-29. doi: 10.1111/j.1539-6975.2009.01286.x.
3
Long-term care over an uncertain future: what can current retirees expect?
Inquiry. 2005;42(4):335-50. doi: 10.5034/inquiryjrnl_42.4.335.
4
Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.
Health Aff (Millwood). 2005 Mar-Apr;24(2):483-90. doi: 10.1377/hlthaff.24.2.483.
5
APOE epsilon4 as a predictor of subjective quality of life in a biracial older person community sample.
J Aging Health. 2003 Nov;15(4):645-60. doi: 10.1177/0898264303256216.
6
Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease.
Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):86-93. doi: 10.1097/00002093-200304000-00006.
7
APOE epsilon4 and low cholesterol as risks for depression in a biracial elderly community sample.
Am J Geriatr Psychiatry. 2002 Sep-Oct;10(5):515-20.
8
National estimates of the quantity and cost of informal caregiving for the elderly with dementia.
J Gen Intern Med. 2001 Nov;16(11):770-8. doi: 10.1111/j.1525-1497.2001.10123.x.
9
The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons.
J Gerontol B Psychol Sci Soc Sci. 2001 Sep;56(5):S285-93. doi: 10.1093/geronb/56.5.s285.
10
Long-term care insurance underwriting: understanding eventual claims experience.
Inquiry. 2000;37(4):348-58.
Zotero 插件